CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(02): 215-225
DOI: 10.1055/a-1724-9569
GebFra Science
Review/Übersicht

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer

Artikel in mehreren Sprachen: English | deutsch
Diana Lüftner
1   Charité University Hospital, Department of Hematology, Oncology and Tumour Immunology, University Medicine Berlin, Berlin, Germany
,
Florian Schütz
2   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
,
Elmar Stickeler
3   Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
,
Peter A. Fasching
4   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Wolfgang Janni
5   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Cornelia Kolberg-Liedtke
6   Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
7   palleos healthcare, Wiesbaden, Germany
8   Phaon Scientific, Wiesbaden, Germany
,
Hans-Christian Kolberg
9   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Christoph Thomssen
10   Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
,
Volkmar Müller
11   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Tanja N. Fehm
12   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
,
Erik Belleville
13   ClinSol GmbH & Co KG, Würzburg, Germany
,
Simon Bader
4   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Michael Untch
14   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Genecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Manfred Welslau
15   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Marc Thill
16   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
,
Hans Tesch
17   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
18   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Michael P. Lux
19   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
,
Achim Wöckel
20   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Bahriye Aktas
21   Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Leipzig, Leipzig, Germany
,
Andreas Schneeweiss
22   National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Rachel Würstlein
23   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Andreas D. Hartkopf
24   Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
› Institutsangaben
Zoom Image

Abstract

Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.



Publikationsverlauf

Eingereicht: 06. Dezember 2021

Angenommen nach Revision: 18. Dezember 2021

Artikel online veröffentlicht:
11. Februar 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany